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Abstract 
Background: Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with 
advanced, non‑squamous, non‑small‑cell lung cancer (NSCLC). However, advanced NSCLC has a 5‑year survival rate 
of below 10%, which is mainly due to therapy resistance. We previously showed that the NSCLC cell line A549 harbors 
different subpopulations including a mesenchymal‑like subpopulation characterized by increased chemo‑ and radio‑
therapy resistance. Recently, therapy resistance in hematological and solid tumors has been associated with increased 
mitochondrial activity. Thus, the aim of this study was to investigate the role of the mitochondrial activity in NSCLC 
chemotherapy resistance.
Methods: Based on MitoTracker staining, subpopulations characterized by the highest 10% (Mito‑High) or low‑
est 10% (Mito‑Low) mitochondrial mass content were sorted by FACS (Fluorescence‑Activated Cell Sorting) from 
paraclonal cultures of the NSCLC A549 cell line . Mitochondrial DNA copy numbers were quantified by real‑time PCR 
whereas basal cellular respiration was measured by high‑resolution respirometry. Cisplatin and pemetrexed response 
were quantified by proliferation and colony formation assay.
Results: Pemetrexed treatment of parental A549 cells increased mitochondrial mass over time. FACS‑sorted para‑
clonal Mito‑High cells featured increased mitochondrial mass and mitochondrial DNA copy number compared to 
the Mito‑Low cells. Paraclonal Mito‑High cells featured an increased proliferation rate and were significantly more 
resistant to cisplatin treatment than Mito‑Low cells. Interestingly, cisplatin‑resistant, paraclonal Mito‑High cells were 
significantly more sensitive to pemetrexed treatment than Mito‑Low cells. We provide a working model explaining 
the molecular mechanism underlying the increased cisplatin‑ and decreased pemetrexed resistance of a distinct 
subpopulation characterized by high mitochondrial mass.
Conclusions: This study revealed that cisplatin resistant A549 lung cancer cells can be identified by their increased 
levels of mitochondrial mass. However, Mito‑High cells feature an increased sensitivity to pemetrexed treatment. Thus, 
pemetrexed and cisplatin target reciprocal lung cancer subpopulations, which could explain the increased efficacy of 
the combination therapy in the clinical setting.
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Background
Lung cancer is the most common cause of cancer-related 
mortality worldwide. This is mainly due to the difficulty 
of early detection and lack of effective treatment meth-
ods, thus more effective treatment options are desper-
ately needed.
Standard therapy for NSCLC includes pemetrexed 
(MTA; commercial name ‘Alimta’), as single agent or 
in combination with either chemo-or radiotherapy [1]. 
MTA is a folic acid antagonist and works by inhibiting 
the synthesis of precursor purine and pyrimidine nucleo-
tides and consequently DNA and RNA synthesis, thereby 
interfering with the proliferation and survival of replicat-
ing cancer cells. Human thymidylate synthase, the major 
target of MTA, is mainly localized in the mitochondria, 
which contain the complete pathway to conduct de novo 
thymidylate biosynthesis [2]. In this context, the expres-
sion of genes involved in pyrimidine metabolism, which 
are targeted by antifolates such as MTA, is highly upreg-
ulated in NSCLC stem cells [3]. However, current strate-
gies of MTA-based therapeutic regimens are challenged 
by relapse of the disease [1].
Mitochondrial metabolism is essential for tumorigen-
esis and cancer cell proliferation [4]. It was shown before 
that a subpopulation of breast cancer stem-like cells can 
be identified by increased mitochondrial mass, which is 
associated with chemotherapy resistance [5]. In NSCLC, 
high mitochondrial activity correlated with increased 
sphere formation capacity and tumor growth, which is 
in agreement with the findings in pancreatic and breast 
cancer [5–8]. Treatment with various DNA damage-
inducing agents affects mitochondrial mass and activ-
ity. In detail, treatment with the DNA damage-inducing 
agent doxorubicin increases mitochondrial mass over 
time in breast and colon cancer cells [9, 10]. It was shown 
that mitochondrial inhibitors in combination with chem-
otherapy can induce synthetic lethality in different cancer 
types [11–13].
Our recent study revealed that adaptation of the treat-
ment schedule optimizes anticancer efficacy of MTA 
and cisplatin combination therapy and further revealed 
the existence of a chemotherapy resistant subpopulation 
in the NSCLC cell line A549 [14]. In a subsequent study 
[15], we showed that the parental, non-treated, A549 cell 
line contains phenotypically distinct subpopulations. In 
detail, holoclonal cells are characterized by an epithelial 
phenotype and feature a high tumor initiating capac-
ity. In contrast, paraclonal cells feature a mesenchymal 
gene expression signature and give rise to fibroblast-like 
colonies characterized by the absence of intact colony 
borders. Interestingly, paraclonal cells were highly resist-
ant to treatment with DNA damage-inducing agents but 
featured a low tumor initiating capacity. Indeed, it is 
well established that epithelial-mesenchymal transition 
(EMT) is also associated with chemotherapy resistance 
[16].
Despite the recognition that mitochondrial activ-
ity has a prominent role in nucleotide synthesis in can-
cer cells, its role in NSCLC chemotherapy resistance is 
relatively unknown. In this study, we take advantage of 
the paraclonal A549 subpopulation as a highly defined 
model to study how mitochondrial activity is associated 
with resistance to MTA and cisplatin, the components 
of the lung adenocarcinoma gold standard combination 
therapy. We found that cisplatin targets cells with a high 
mitochondrial activity. However, this subpopulation fea-
tures an increased sensitivity to MTA treatment. Thus, 
our study revealed that MTA and cisplatin target differ-
ent lung cancer subpopulations, which might explain the 
increased efficacy of the combination therapy in the clini-
cal setting.
Materials and methods
Cell culture and media
The isolation of paraclonal subpopulations from the 
NSCLC cell line A549 (CCL-185) was described in detail 
in our previous publications [14, 15]. Purified A549 para-
clonal cultures (subclone 3.4) were cultured in Dulbecco’s 
modified Eagle’s medium nutrient mixture F-12 Ham 
(DMEM/F12), supplemented with 9% fetal bovine serum, 
1% penicillin/streptomycin solution and 1% l-Glutamine 
at 37 °C in a humidified 5%  CO2 incubator. Cell lines were 
DNA fingerprinted as described previously [14, 15].
Immunofluorescence microscopy
Four thousand A549 cells were seeded into 4-well cham-
ber slides, each well containing 1  mL culture medium. 
After 2–3  days of culture, medium was removed and 
attached cells were washed with PBS for 5 min at room 
temperature. PBS was replaced by 1  mL of DMEM/F12 
medium containing 200 nM MitoTracker Deep Red. Cells 
were incubated at 37  °C for 30  min and subsequently 
washed with 1  mL PBS. Cells were fixed with 0.5  mL 
FIX/PERM solution for 15  min at room temperature. 
After fixation, cells were washed with PBS and subse-
quently mounted with mounting media containing DAPI. 
Keywords: Lung cancer, NSCLC, Chemotherapy, Cisplatin, Pemetrexed, Resistance, Mitochondrial activity, 
Mitochondrial mass
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Fluorescence microscopy images were acquired on a 
Leica DMI4000 microscope.
Flow cytometry
A549 cells were seeded into 15-cm dishes (1 × 106 cells 
per dish) on day 0. On day 1, MTA was added at a final 
concentration of 1 µM and plates were incubated at 37 °C 
as indicated for either 24, 48 or 72 h, respectively. Sub-
sequently, 0.5 × 106 cells were stained in culture medium 
with 200 nM MitoTracker Deep Red for 30 min at 37 °C. 
Cells were washed once with PBS and fixed by FIX/
PERM solution. After fixation, cells were suspended in 
FC buffer (PBS with 2% FBS, 0.05%  NaN3, 2 mM EDTA) 
containing 0.5  µg/mL DAPI and analysed using a FACS 
LSR2 flow cytometer.
Western blot analysis
A549 cells were seeded into 6-well plates (0.15 × 106 
cells per well) and treated with MTA as described above. 
Subsequently, cells were lysed in RIPA buffer containing 
1 × protease and phosphatase inhibitor cocktails. Pro-
tein concentration was measured by Pierce™ BCA Pro-
tein Assay Kit. Equal amounts of protein lysates (21 µg/
lane) were resolved by SDS-PAGE, and transferred onto 
nitrocellulose membranes, which was then blocked in 
 Intercept® (TBS) Blocking Buffer for 1 h at room temper-
ature and blotted with specific primary antibodies at 4 °C 
overnight on an orbital shaker. IRDye 680LT-conjugated 
goat anti-mouse IgG and IRDye 800CW-conjugated goat 
anti-rabbit IgG from Li-COR Biosciences were used at 
1:5000 dilutions. Finally, signals of membrane-bound sec-
ondary antibodies were imaged and quantified using the 
Image Studio Lite System.
Titration and toxicity analysis of MitoTracker dyes
A549 Rho0 cells were generated by continuous expo-
sure for 3  month to ethidium bromide (50  ng/mL) as 
described previously [17]. Duplex PCR was used to 
validate the phenotype of A549 Rho0 cells [18]. Paren-
tal A549 and A549 Rho 0 cells were stained with 
MitoTracker Red or MitoTracker Deep Red at increas-
ing concentrations. Stained cells were analysed by flow 
cytometry as described above. To evaluate toxicity, A549 
paraclonal cells were stained with MitoTracker Deep Red 
at increasing concentrations and subsequently seeded 
into 6-well plates (5000 cells/well). After 1-week, cells 
were stained with crystal violet (1% in 50% ethanol).
Fluorescence activated cell sorting (FACS)
1 × 106 paraclonal A549 cells were seeded into 15  cm 
dishes. Once 70–80% confluence was reached, i.e. after 
2 or 3  days, exponentially dividing paraclonal A549 
cells were detached by TrypLE and re-suspended into 
cultured medium. Trypan blue staining was used to 
exclude dead cells and to determine cell titers. Approxi-
mately 80 × 106 paraclonal cells were stained with 25 nM 
MitoTracker Deep Red for 30 min in cell culture medium 
at 37  °C. After staining, cells were washed once with 
PBS for 5  min. Subsequently, cells were resuspended 
in 5  µM  Vybrant® DyeCycle™ Violet staining solution 
(in PBS with 2%FBS). ARIA III (FACS Diva 8.0.1, BD). 
Finally, two regions containing each 10% of the total cell 
single cell population, either with the highest or lowest 
MitoTracker signal intensity, i.e. “Mito-High” and “Mito-
Low” subpopulations, respectively, were FACS sorted 
using an ARIA III cell sorter (FACS Diva 8.0.1, BD). The 
detailed FACS gating strategy is depicted in Fig. 3.
Real‑time PCR (qPCR)
Sorted cells (Mito-High 10% and Mito-Low 10%) were 
washed with PBS. DNA genome was isolated and puri-
fied with GenElute™ Mammalian Genomic DNA Mini-
prep Kit. qPCR analyses were performed in triplicate on 
a 7500 Fast Real-Time PCR System (Applied Biosystems) 
with a new fluorescent DNA-binding dye-based (similar 
with SyberGreen I)  GoTaq® qPCR Master Mix. qPCR 
cycling parameters are used as follows: 10 µL-reaction 
system, Initial denaturation 95 °C, 2 min, 1 cycle; Dena-
turation 95 °C, 3  s, Annealing extension 68 °C, 30  s, 40 
cycles. Relative quantification (mtDNA:nDNA ratio) was 
calculated using the ΔΔCt method upon targeting of 
nuclear-encoded genes(human β-globin_Fwd: 5′-GGC 
TGT CTC CTA GCA ACG AC-3′, human β-globin_Rev: 
5′-TGC ATA CCA GCT CTC ACC TG-3′ and mitochon-
drial genome (221  bp human mitochondrial genome 
fragment_Fwd: 5′-CCC CAC AAA CCC CAT TAC TAA 
ACC CA-3′, human mitochondrial genome fragment_
Rev: 5′-TTT CAT CAT GCG GAG ATG TTG GAT 
GG-3′) [19].
High‑resolution respirometry
High-resolution respirometry was performed on sorted 
Mito-High and Mito-Low subpopulations. In detail, 
approximately 1 × 106 cells were resuspended in 2  mL 
of mitochondrial respiration medium (110 mM sucrose, 
0.5  mM EGTA, 3.0  mM  MgCl2, 80  mM  KCl, 60  mM 
K-lactobionate, 10 mM  KH2PO4, 20 mM taurine, 20 mM 
hepes, 1.0 g/l BSA, pH 7.1). Sorted subpopulations were 
analyzed at 37  °C using an  Oroboros® oxygraphy tool 
(Oxygraph-2  k, Oroboros Instruments, Innsbruck, Aus-
tria), with chamber volumes set at 2 ml as published 
previously by our group [20]. Basal coupled endogenous 
respiration of intact cells (oxygen consumption with-
out the addition of exogenous substrate) was measured 
and recorded using the linear rate of oxygen consump-
tion. DatLab software was used for data acquisition and 
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analysis, which included calculation of the time deriva-
tive for oxygen concentration and correction for instru-
mental background oxygen flux.
Cisplatin and MTA response assays
To quantify cell numbers after chemotherapy treatment, 
paraclonal A549 cells were stained for FACS sorting as 
described above. Subsequently, 10,000 Mito-High (10%) 
or Mito-Low (10%) cells per well were FACS-sorted into 
6-well plates containing 2 mL culture medium with dif-
ferent concentrations of cisplatin (0, 0.25, 0.5, 1, 2, 4 µM) 
and MTA (0, 3.125, 6.25, 12.5, 25, 50 µM). Cells were cul-
tured at 37 °C in a humidified 5%  CO2 incubator. After 1 
week, cells from three wells per treatment were harvested 
using ThypLE. Cell titers were determined using a hemo-
cytometer and trypan blue (final concentration 0.1%) for 
dead cell exclusion. Experiments were repeated indepen-
dently three times.
To quantify colony numbers after chemotherapy treat-
ment, 700 cells per well were FACS-sorted into 6-well 
plates and treated with chemotherapy as described 
above. After 2 weeks, colonies were stained by crystal 
violet solution (1% final concentration in 50% ethanol). 
Colony formation was quantified by an automated colony 
counting system (GelCount, Oxford Optronix).
Statistics
Statistical analyses were performed using GraphPad 
Prism 6.03 (GraphPad Software Inc., http://www.graph 
pad.com) unless otherwise indicated. In all studies, data 
represent biological replicates (n) and are depicted as 
mean values ± s.d. or mean values ± SEM as indicated 
in the figure legends. Comparison of mean values was 
conducted with two-tailed Student’s t test and two-way 
ANOVA with Tukey’s multiple comparisons test as indi-
cated in the figure legends. In all analyses, p values less 
than 0.05 were considered statistically significant.
Additional information and resources are included in 
the Additional file 1: Table S1.
Results
MitoTracker Deep Red dye localizes to the mitochondria 
and confers toxicity at higher doses
We established an experimental approach to investigate 
whether mitochondrial activity is associated with chemo-
therapy resistance. In detail, we previously showed that 
distinct subpopulations co-exist in the parental NSCLC 
cell line A549, which are characterized by significant 
differences in EMT status [15]. To exclude the effect of 
EMT-associated parameters, we focused our analysis to 
one subpopulation only, A549 paraclonal cells, which are 
highly resistant to DNA-damaging therapy (Additional 
file 2: Figure S1a).
To obtain a negative control to assay mitochondrial 
activity, we depleted mitochondrial DNA from paren-
tal A549 cells (A549 Rho 0 cells) by continuous eth-
idium bromide treatment as published previously 
[17]. Indeed, whereas mitochondrial DNA was read-
ily detectable in parental A549 cells, no mitochondrial 
DNA was detectable in A549 Rho 0 cells (Additional 
file  2: Figure S1b). In agreement, high-resolution 
respirometry revealed that only background activity 
of the mitochondrial respiration complex I, II, and IV 
(encoded by mitochondrial DNA) was detectable in 
A549 Rho 0 cells (Additional file 2: Figure S1c). Analy-
sis by light microscopy revealed that the mitochondrial 
DNA ablation protocol induced obvious morphological 
changes (Additional file 2: Figure S1d), i.e. cells became 
larger and more mesenchymal like. Our analysis by flow 
cytometry revealed that the basal autofluorescence lev-
els in the PE-Texas Red Channel of A549 Rho 0 cells 
were tenfold higher compared to parental A549 cells 
(Additional file 3: Figure S2, compare unstained signals, 
i.e. red peaks). This increase in autofluorescence of Rho 
0 cells might be explained due to the supplementation 
of the growth medium with ethidium bromide, whose 
absorbance and emission spectra are a near-perfect 
match with those of PE-Texas Red (Additional file  3: 
Figure S2b, https ://www.therm ofish er.com/order /spect 
ra-viewe r).
MitoTracker dyes are frequently used to quantify 
mitochondrial activity in cancer cells (reviewed in 
[21]). According to the manufacturer, MitoTracker Red 
CMXRos is a fixable red-fluorescent dye that stains mito-
chondria in live cells and its accumulation is dependent 
on the mitochondrial membrane potential. However, 
when we stained A549 Rho 0 with the Rosamine-based 
dye MitoTracker RED CM-H2Ros at a concentration 
of >1  nM, average signal intensity increased more than 
tenfold compared to non-stained cells (Additional file 3: 
Figure S2). Therefore, we concluded that MitoTracker 
RED CM-H2Ros is not a suitable dye to monitor mito-
chondrial activity in A549 cells under our experimental 
conditions.
In breast cancer, increased mitochondrial mass is asso-
ciated with increased, sphere/tumor formation capac-
ity and chemotherapy resistance [5]. Staining with the 
mitochondrial mass specific dye MitoTracker Deep Red 
resulted in a perinuclear staining pattern indicative of a 
mitochondrial localization in both, parental and para-
clonal A549 cells (Fig.  1a). Analysis by flow cytometry 
revealed that MitoTracker Deep Red signal intensity 
increased in a dose dependent manner (Fig.  1b). How-
ever, higher concentrations of MitoTracker Deep Red 
decreased colony formation capacity of paraclonal A549 
cells (Fig. 1c). Therefore, MitoTracker Deep Red was used 
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at a concentration of 25 nM for staining cells in all subse-
quent experiments.
MTA treatment increases mitochondrial mass over time
We investigated whether MTA treatment increases mito-
chondrial mass in NSCLC A549 cells. Indeed, treatment 
of parental A549 cells for 24 h with 1 µM MTA increased 
mitochondrial mass, which was further augmented after 
48 and 72  h, respectively (Fig.  2a, see Additional file  4: 
Figure S3a for the gating strategy). Additionally, these 
results further corroborated our findings that staining 
with MitoTracker Deep Red is suitable to monitor rela-
tive changes in mitochondrial mass.
Mitochondrial content and cell size both increase dur-
ing progression through the cell cycle. Consequently, 
mitochondrial content has to be normalized to the cell 
cycle phase, as described in the literature before [22]. 
Therefore, we established a flow cytometry protocol, 
which included simultaneous staining for mitochondrial 
mass and DNA content (Additional file  4: Figure S3b). 
MTA treatment for 24  h induces a G1/S-phase arrest 
in parental A549 cells (Fig.  2b). The G1-phase arrest 
was further augmented by MTA treatment for 48  h, 
as we published before [14, 23]. This indicates that the 
observed increase in mitochondrial mass after treat-
ment with 1 µM MTA is not sufficient to overcome the 
induction of a cell cycle arrest. In this study, we addition-
ally observed a transition into the later cell cycle phases, 
e.g. S/G2/M-phase, 72 h after starting the treatment with 
MTA (Fig. 2b). The finding that 72 h of MTA treatment 
induces a robust  G2/M-phase cell cycle arrest by was fur-
ther corroborated by the accumulation  G2/M cell cycle 
checkpoint proteins, i.e. Cyclin B1 and phosphorylated 
Cdc2, (reviewed in [24]). We previously showed that 
48  h of MTA treatment induces DNA damage as indi-
cated by increased levels of phosphorylated H2AX [14, 
23]. Indeed, levels of H2AX phosphorylation after MTA 
treatment were further increased after 72 h compared to 
Fig. 1 Localization, titration and toxicity of MitoTracker Deep Red staining in A549 cells. a Localization of MitoTracker Deep Red staining (red) in 
parental (top) and paraclonal A549 cells (bottom) analyzed by immunofluorescence microscopy. Cells were counterstained with DAPI. b Titration of 
MitoTracker Deep Red staining. Flow cytometry‑based analysis of signal intensity from mesenchymal paraclonal A549 cells after staining with the 
indicated concentrations of MitoTracker Deep Red dye. c Assessing toxicity of MitoTracker Deep Red staining by colony formation assay. Colonies 
were stained by crystal violet 2 weeks after treatment with MitoTracker Deep Red dye at the indicated concentrations, e.g. 0, 10, 25, 50, 100 and 
200 nM
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48 h Fig. 2c). Interestingly, we observed that the increase 
in cellular mitochondrial mass at 48 and 72  h after the 
start of the MTA treatment was detectable in both 
G1-phase and S/G2/M-phase cells, respectively. Hence, 
the increase in mitochondrial mass after MTA treatment 
is independent of the cell cycle phase (Fig. 2a, middle and 
bottom panel).
A549 subpopulations isolated based on mitochondrial 
mass differ in mitochondrial DNA content and basal 
respiratory activity
To exclude the effect of EMT-associated parameters, we 
limited our analysis to A549 paraclonal cells, which are 
highly resistant to DNA-damaging therapy (Additional 
file  2: Figure S1a). We developed a FACS sorting strat-
egy to isolate subpopulations based on their differential 
MitoTracker Deep Red staining intensities (Fig.  3). In 
detail, staining for DNA content allowed us to exclude 
debris (Fig. 3a, b) and doublets (Fig. 3c). Finally, we gated 
for two regions containing each 10% of the total cell sin-
gle cell population, either with the highest or lowest 
MitoTracker signal intensity, i.e. “Mito-High” and “Mito-
Low” subpopulations, respectively (Fig. 3d).
We adjusted the layout of our sorting gates so the cell 
cycle distribution of the sorted populations was not only 
similar with the non-sorted A549 paraclonal population 
but also matched each other (Fig.  3e). Staining of live 
cells with Hoechst results in toxicity at higher concen-
trations; therefore, we used a low Hoechst concentra-
tion for our FACS protocol. The cell cycle distribution 
histograms obtained by Hoechst staining during our 
live-cell sorting protocol did not feature the characteris-
tic G1, S and G2/M phases (Fig. 3e), which we observed 
after DAPI staining of fixed and permeabilized cells 
Fig. 2 MTA treatment increases mitochondrial mass of lung cancer A549 cells. a Changes in mitochondrial mass after treatment with 1 µM MTA 
were quantified by FACS analysis. In detail, to quantify changes in mitochondrial mass, a gate was set so 5% of untreated A549 cells (24 h) were 
scored as positive for mitochondrial mass (see Additional file 4: Figure. S3 for details). The same gate was applied to all samples. The total population 
of cells was further divided into two subpopulations according to their respective DNA content, e.g. G1‑phase cells and S/G2/M‑phase cells. 
Shown are the mean values and the standard error of mean, N = 4. p value was determined by unpaired and two‑tailed Student’s t test, *p < 0.05, 
**p = 0.0076. b Cell cycle distribution after MTA treatment. G1‑ and S/G2/M‑phase gates were adjusted for each sample to compensate for slight 
shifts in linear DAPI fluorescence intensity due to treatment‑induced changes in FSC/SSC signal intensity. c Analysis of parental A549 cell protein 
expression after MTA treatment by western blot.  G2M cell cycle checkpoint proteins: Cyclin B1, Cdc2 and p‑Cdc2
Tyr15. DNA damage response protein: 
p‑H2AXSer139. Signal intensities were normalized to the internal control (β‑actin) on the same blot. The control condition, i.e. untreated A549 cells 
(24 h), was set to unity. d MTA treatment for 48 h induced morphological changes in parental A549 cells
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(Fig.  2b). However, the live-cell Hoechst staining never-
theless allowed us to match the cell cycle distribution of 
the sorted subpopulations by adjusting the sorting gates 
accordingly (Fig. 3e).
Our subsequent analysis of the sorted subpopula-
tions revealed that the mitochondrial DNA content and 
basal respiration (indicator of mitochondrial function) 
was significantly higher in the Mito-High compared 
Fig. 3 FACS‑based isolation of Mito‑High and Mito‑Low subpopulations from paraclonal A549 cells. For cell sorting, the following gates were 
sequentially applied: a Debris exclusion based on the cell size and granularity (FSC‑A vs SSC‑A, respectively), e.g. gate P1 includes 96.4% of total 
population. b Second round of debris exclusion based on DNA content (Alexa Fluor 405‑A, e.g. gate P2 includes 97.1% of gate P1. c Single cell 
gate based on DNA content measurement (Alexa Fluor 405‑A vs Alexa Fluor 405‑W, e.g. gate P3 includes 73.6% of gate P2. d Based on MitoTracker 
Deep Red staining (APC‑a), sorting gates P4 and P5 were defined so each contains 10% of the total single cell population, either with the highest or 
lowest MitoTracker signal intensity, i.e. “Mito‑High” and “Mito‑Low”, respectively
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Fig. 4 Characterization of the sorted Mito‑High and Mito‑Low subpopulations from paraclonal A549 cells. a Relative quantification of mtDNA 
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to the Mito-Low subpopulation, respectively (Fig.  4). 
In summary, we developed a sorting strategy based on 
mitochondrial mass, which allowed us to isolate from 
paraclonal A549 cultures distinct subpopulations charac-
terized by significant differences in mitochondrial DNA 
copy numbers and activity.
High mitochondrial mass is associated with increased 
cellular proliferation and cisplatin resistance
Cellular proliferation, i.e. cell numbers 1 week after 
sorting in the absence of treatment, was significantly 
increased in the Mito-High compared to the Mito-Low 
paraclonal A549 subpopulation (Fig.  5a). Additionally, 
absolute cell numbers were also higher after cisplatin 
treatment at different doses (Fig.  5a). However, after 
adjusting for the basal difference in proliferation, rela-
tive inhibition of proliferation by cisplatin treatment was 
identical for Mito-Low and Mito-High paraclonal A549 
subpopulations (Fig. 5b).
In tumors, eradication of the capacity for unlimited 
proliferation of all stem cells is required for the preven-
tion of recurrences [25]. In vitro, the clonogenic assay is 
the method of choice to test for the capacity of a cell to 
undergo “unlimited” division and thus has been used as a 
surrogate assay to evaluate tumor initiation capacity and 
stem cell status [26]. Indeed, in the absence of treatment, 
absolute colony numbers from Mito-High subpopula-
tions were significantly higher compared to the colonies 
formed after seeding Mito-Low paraclonal A549 cells 
(Fig.  5c, e). Additionally, absolute colony numbers were 
also higher after cisplatin treatment at different doses. In 
contrast to the results obtained by analyzing cell num-
bers, after adjusting for the basal difference in colony for-
mation, the colony formation capacity of Mito-High cells 
was significantly more resistant to cisplatin treatment 
compared to Mito-Low cells (Fig. 5d).
High mitochondrial mass is associated with increased MTA 
sensitivity
Cisplatin plus MTA is the standard regimen for first-line 
treatment of advanced NSCLC [27]. Interestingly, both 
absolute and relative cellular proliferation of cisplatin-
resistant Mito-High cells was significantly more affected 
by MTA treatment compared to Mito-Low cells (Fig. 6a, 
b). Similarly, both the absolute and the relative colony 
formation capacity of Mito-High cells were significantly 
more reduced by MTA treatment compared to Mito-Low 
cells (Fig. 6c–e, respectively).
In summary, our experiments indicate that MTA treat-
ment increases mitochondrial mass in parental A549 
NSCLC cells. Interestingly, relative to Mito-Low cells, 
Mito-High paraclonal A549 cells are resistant to cisplatin 
but sensitive to MTA treatment.
Discussion
Chemotherapy resistance is a major obstacle in can-
cer therapy (reviewed in [28]). It was shown before that 
mitochondrial activity is associated with chemotherapy 
resistance in breast cancer [5]. In agreement, our study 
revealed that also in lung cancer, response to chemo-
therapy is dependent on the status of the mitochondrial 
metabolism.
Our study revealed that mitochondrial mass increased 
after MTA treatment (Fig.  3a). In agreement, in human 
colorectal adenocarcinoma cells, inhibition of nucleo-
tide synthesis by treatment with the ribonucleotide 
reductase inhibitor Gemcitabine (2′,2′-difluorodeoxy-
cytidine, a pyrimidine nucleoside analogue) results in 
a significant increase in mitochondrial mass quantified 
by MitoTracker Deep Red staining [29]. Recently, it was 
shown that the increase in mitochondrial mass in cancer 
cells after exposure to ionizing radiation is dependent 
on increased calcium accumulation in the mitochon-
dria [30]. Previously, it was shown that the induction of 
mitochondrial biogenesis by etoposide is dependent on 
ATM and AMPK [31]. Thus, additional experiments will 
be required to clarify the underlying mechanism respon-
sible for the increase in mitochondrial mass after MTA 
treatment in A549 lung cancer cells. Thus, it will be 
interesting to elucidate if the treatment-induced increase 
of mitochondrial mass in parental A549 cells (Fig.  2) is 
limited to Mito-Low cells or whether Mito-High cells 
can increase mitochondrial content to even higher levels 
after chemotherapy. Additionally, it was shown that cis-
platin treatment can induce morphological changes, e.g. 
mitochondrial fusion [32]. Thus, it would be interesting 
to test whether chemotherapy not only induces changes 
in mitochondrial mass but also gives rise to functional 
and morphological changes.
The cancer stem cell hypothesis postulates that differ-
ent cellular subpopulations do exist in tumors (reviewed 
in [33]). Cancer stem-like cells can self-renew and give 
rise to transient amplifying cells, which are responsi-
ble for bulk tumor cell proliferation. Quantifying tumor 
cell proliferation serves as an in vitro surrogate assay to 
quantify proliferation of bulk tumor cells whereas quan-
tifying colony or sphere formation capacity serves as an 
in vitro surrogate assay to assess tumor-initiation capac-
ity. Treatment with increasing doses of cisplatin reduces 
both, absolute and relative proliferation of all tested 
populations (Fig.  5a, b, respectively). Surprisingly, nor-
malized proliferation of mito-Low and mito-High cells 
was equally inhibited by cisplatin treatment (Fig.  5b). 
This indicates that the effect of cisplatin on cellular 
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proliferation is independent of the mitochondrial con-
tent. Alternatively, the increased absolute prolifera-
tion rate of mito-High cells might be more sensitive to 
cisplatin treatment thereby cancelling out the protective 
effect of an increased mitochondrial content.
Lung cancer tumor-initiating cells gave rise to chem-
otherapy-resistant colonies in  vitro [34]. Also, breast 
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cancer cells characterized by increased mitochondrial 
mass featured an increased tumor initiation capacity and 
gave rise to chemotherapy resistant colonies in vitro [5]. 
In agreement, we found that the absolute colony forma-
tion capacity of untreated Mito-High cells was increased 
compared to Mito-Low cells (Fig.  5c). Interestingly, the 
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relative colony formation capacity of Mito-High cells was 
resistant to cisplatin treatment (Fig.  5d). This indicates 
that the effect of cisplatin on the relative colony forma-
tion capacity is dependent of mitochondrial content. In 
summary, untreated paraclonal A549 Mito-High cells 
feature an increased absolute proliferation rate and col-
ony formation capacity. Interestingly, the relative effect of 
cisplatin on cellular proliferation might be independent 
of mitochondrial content whereas the effect of cisplatin 
on colony formation is dependent on the mitochondrial 
content. Further experiments will be required to eluci-
date the specific mitochondrial features rendering col-
ony-forming cells resistant to cisplatin.
We found that the absolute proliferation rate of 
untreated Mito-High cells was increased compared to 
Mito-Low cells (Figs. 5a and 6a). In yeast, it was shown 
that dNTP pools are limiting for normal DNA replication 
[35]. In mammalian cells, the de novo pyrimidine biosyn-
thetic enzyme dihydroorotate dehydrogenase (DHODH) 
is localized at mitochondria and is physically associated 
with the mitochondrial respiratory complex III [36]. 
Thus, we speculate that an increase in mitochondria-
dependent nucleotide synthesis is responsible for the 
increased proliferation rate of Mito-High cells.
Induction of DNA damage induces upregulation of 
dNTP levels in bacteria and yeast (reviewed in [37]). In 
detail, initiation of the DNA damage response activates 
respiration and thereby enlarging dNTP pools to pro-
mote cell survival in budding yeast [38]. In mammalian 
cells, the increase in nucleotide levels upon DNA dam-
age induction is less pronounced than in single cell 
organisms (reviewed in [37]). However, in human breast 
cancer cells, treatment with the doxorubicin marginally 
increased purine nucleotide but significantly increased 
pyrimidine nucleotide levels [39]. Thus, we propose the 
following working model to explain the observed cispl-
atin resistance of Mito-High cells. DNA damage induc-
tion leads to the activation of the DNA damage response, 
which leads to a mitochondrial respiration-dependent 
increase of dNTP pools thereby increasing DNA repair 
capacity and and thus cisplatin resistance (Fig. 7). Mito-
High cells contain more mitochondria per cell than 
Mito-Low cells, resulting in a relative increase in mito-
chondrial-dependent dNTP synthesis and subsequently 
increased DNA repair capacity, which could explain the 
increased cisplatin resistance of Mito-High cells (Fig. 7).
Surprisingly, we found that cisplatin-resistant Mito-
High cells featured an increased MTA sensitivity (Fig. 6). 
In contrast to cisplatin, MTA does not directly induce 
DNA damage. MTA blocks several enzymes involved 
in nucleotide synthesis, its main target being thymi-
dylate synthetase, which is critical for the synthesis of 
dTMP [40]. MTA-induced nucleotide depletion will lead 
to DNA replication fork stalling and activation of the 
DNA damage response. Thus, according to our working 
model for cisplatin resistance (Fig.  7), we would con-
clude that Mito-High cells are more MTA resistant due 
to the relative increase in nucleotide levels. However, 
↑mito respiration
↓ Mito-Low ↑Mito-HighParaclonal A549 cells
↑dNTP pools
↑DNA repair
↑cisplatin
resistance
WORKING MODEL #1: ↑ Mito-High = ↑ cisplatin resistance
↓mito respiration
↓dNTP pools
↓DNA repair
↓cisplatin
resistance
↑mito respiration
↑dNTP pools 
↑DNA repair
↑cisplatin
resistance
Cisplatin
↑DNA 
damage
↑DDR 
activation
Fig. 7 Working model explaining the increased cisplatin resistance of Mito‑High cells. See text for details
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our experiments indicated the opposite, how can this be 
explained? As reviewed recently, not only are the overall 
dNTP levels important for genome stability, but also the 
balance between individual dNTPs since distortions in 
dNTP ratios can lead to DNA polymerase incorporation 
errors (reviewed in [37]. Thus, to explain the increased 
MTA sensitivity of Mito-High cells, we propose the fol-
lowing working model (Fig.  8), which is based on two 
assumptions: First, we assume that the dNTP pools 
are decreased in sorted Mito-Low and increased in 
Mito-High cells compared to paraclonal A549 cells. As 
discussed above, we speculate that the increased prolifer-
ation rate of Mito-High cells is due to an increased mito-
chondria-dependent nucleotide synthesis, i.e. increased 
dNTP pools. Second, we assume that MTA treatment 
reduces dGTP and dTTP levels in all cells four-fold 
compared to parental cells. Indeed, MTA treatment of 
HCT116 colorectal cancer cells reduced dGTP and dTTP 
levels by a factor of ~ fourfold compared to untreated 
controls wheras dATP and dCTP levels remained con-
stant [41]. Thus, our working model predicts that the rel-
ative nucleotide pool imbalance will be most pronounced 
in Mito-High cells, which could explain the increased 
MTA sensitivity of Mito-High cells. Obviously, additional 
studies will be required to confirm the underlying molec-
ular mechanisms of our working model. Additionally, it 
was shown before that ATP-binding cassette proteins are 
involved in cisplatin resistance [42]. Thus, further experi-
ments will be required to determine if these proteins are 
associated with mitochondrial mass in the context cispl-
atin and MTA resistance.
The most significant limitation of our study is that the 
analysis is restricted to the A549 paraclonal subpopula-
tion only. Our preliminary experiments revealed that 
sorting parental A549 cells according to mitochondrial 
mass staining for the top and bottom 5% subpopulations 
selects for paraclonal and holoclonal cells, respectively 
(data not shown). Thus, sorting cell lines for subpopula-
tions according to mitochondrial mass does not address 
for differences in the EMT status. We previously showed 
that chemotherapy resistance is more than 100-fold 
higher in paraclonal compared to holoclonal cells [15]. 
Thus, isolated A549 subpopulations represent an ideal 
system to examine the association between mitochon-
drial mass and chemotherapy resistance without bias 
from the EMT status (Additional file 2: Figure S1a). Nev-
ertheless, additional studies will be necessary to confirm 
that the observed association of mitochondrial activity 
with cisplatin resistance and MTA sensitivity is not lim-
ited to the highly resistant A549 paraclonal subpopu-
lation only but applies to lung cancer cells in general. 
Additionally, quantifying mitochondrial dNTP pools 
would further corroborate our working models.
Accumulating evidence indicates that mitochondrial 
metabolism is required for tumorigenesis (reviewed 
in [4]. More recently, mitochondrial metabolism has 
been identified as a potentially fruitful target for cancer 
therapy. Indeed, several drugs targeting mitochondrial 
WORKING MODEL #2: ↑ Mito-High = ↑ pemetrexed sensitivity
↑mito respiration
↓ Mito-Low ↑Mito-High Paraclonal A549 cells
MTA
↑DNA 
damage
↑DDR 
activation
↑dNTP pools
↓mito respiration
↓dNTP pools
↑mito respiration
↑dNTP pools
TGAC TGAC TGAC
Imbalance of
dNTP pools
(TG vs AC)
4x ↑↓
Fig. 8 Working model explaining the increased MTA sensitivity of Mito‑High cells. See text for details
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metabolism are currently under clinical investigation as 
novel anticancer therapies, either alone or as combina-
tion therapy (reviewed in [43]). Our study revealed that 
Mito-High cells are relatively resistant to cisplatin but 
sensitive to MTA treatment. Thus, targeting the mito-
chondrial metabolism might improve the anticancer 
activity of some drugs but might confer resistance for 
other agents. Therefore, it will be important to elucidate 
the exact molecular mechanism underlying any combi-
nation therapy targeting the mitochondrial metabolism. 
Hence, our study warrants further experiments to eluci-
date the critical role of mitochondrial metabolism in can-
cer growth and therapy resistance.
Conclusion
Cisplatin resistant non-small cell lung cancer cells are 
characterized by high levels of mitochondrial mass and 
are susceptible to MTA treatment. Thus, MTA and cispl-
atin target reciprocal lung cancer subpopulations, which 
could explain the increased efficacy of the combination 
therapy in the clinical setting.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 5‑019‑1037‑1.
Additional file 1: Table S1. Key resources.
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ing. a Flow cytometry analysis of A549 and A549 Rho0 cells staining with 
MitoTracker Red CMXRos (Mitochondrial activity dye). Different concentra‑
tions of MitoTracker Red CMXRos dye were tested, e.g. 0.25, 0.5, 1, 5, 10, 25, 
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and PE‑Texas Red.
Additional file 4: Figure S3. Gating strategy to analyze the increase of 
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